Get the Stockscreener App
50.49
2.77%
1.36
After Hours:
49.72
-0.77
-1.53%
Soleno Therapeutics Inc stock is traded at $50.49, with a volume of 765.28K.
It is up +2.77% in the last 24 hours and up +3.15% over the past month.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
See More
Previous Close:
$49.13
Open:
$49.28
24h Volume:
765.28K
Relative Volume:
1.48
Market Cap:
$1.96B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-16.66
EPS:
-3.03
Net Cash Flow:
$-24.94M
1W Performance:
+4.88%
1M Performance:
+3.15%
6M Performance:
+17.97%
1Y Performance:
+71.09%
1-Day Range:
$48.54
$51.08
1-Week Range:
$46.31
$51.08
52-Week Range:
$21.30
$55.56
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
203 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
Soleno Therapeutics' SWOT analysis: rare disease stock eyes FDA approval By Investing.com - Investing.com UK
145,110 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Bought by Driehaus Capital Management LLC - MarketBeat
Piper Sandler maintains price target on Soleno Therapeutics - Investing.com
Soleno Therapeutics (NASDAQ:SLNO) Shares Up 4.5% - Defense World
Is it possible to buy Soleno Therapeutics Inc(SLNO) shares at a good price now? - US Post News
Samlyn Capital LLC Purchases 282,122 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Ratio Examination: Soleno Therapeutics Inc (SLNO)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Samlyn Capital LLC Has $20.44 Million Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review - MSN
Avoro Capital Advisors LLC Has $85.34 Million Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Analyzing Soleno Therapeutics Inc (SLNO) After Recent Trading Activity - Knox Daily
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Holdings Lifted by Avoro Capital Advisors LLC - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Sold by Ally Bridge Group NY LLC - Defense World
Get in on Soleno Therapeutics Inc’s (SLNO) buy-in window today! - SETE News
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Holdings Boosted by Victory Capital Management Inc. - Defense World
Soleno Therapeutics, Inc.(NasdaqCM: SLNO) added to S&P Global BMI Index - Marketscreener.com
Objective long/short (SLNO) Report - Stock Traders Daily
Rhumbline Advisers Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Rhumbline Advisers Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics (NASDAQ:SLNO) Rating Reiterated by Cantor Fitzgerald - MarketBeat
Soleno Therapeutics’ (SLNO) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Position Trimmed by Quest Partners LLC - Defense World
Soleno Therapeutics (NASDAQ:SLNO) Reaches New 52-Week High at $54.32 - MarketBeat
Sofinnova Investments Inc. Has $22.62 Million Stock Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewswire
Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference - Yahoo Finance
Insider Sale Alert: Soleno Therapeutics Inc [SLNO] – Is it Time to sell? - Knox Daily
88,799 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Bought by Bank of New York Mellon Corp - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume - Defense World
Bank of New York Mellon Corp Acquires Shares of 88,799 Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Capnia Inc stock soars to 52-week high of $53.85 amid staggering growth - Investing.com Canada
Soleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume - MarketBeat
500: Something went wrong - Investing.com
Capnia Inc stock soars to 52-week high of $53.85 amid staggering growth - Investing.com Australia
Capnia Inc stock soars to 52-week high of $53.85 amid staggering growth By Investing.com - Investing.com South Africa
Capnia Inc stock soars to 52-week high of $53.85 amid staggering growth - Investing.com India
Capnia Inc stock soars to 52-week high of $53.85 amid staggering growth - Investing.com UK
TD Asset Management Inc Raises Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
TD Asset Management Inc Boosts Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Rating of “Buy” by Brokerages - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $67.14 Average Price Target from Analysts - MarketBeat
Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc. - GuruFocus.com
Soleno Therapeutics, Inc. Forecasted to Post Q3 2024 Earnings of ($0.56) Per Share (NASDAQ:SLNO) - Defense World
Equities Analysts Offer Predictions for Soleno Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:SLNO) - MarketBeat
Soleno’s DCCR under FDA priority review for hyperphagia in PWS - Prader-Willi Syndrome News
Soleno Therapeutics Inc [SLNO] Shares Jump Approximately 900.00% Over the Year - Knox Daily
Soleno Therapeutics (NASDAQ:SLNO) Coverage Initiated by Analysts at HC Wainwright - Defense World
Analyst starts Soleno Therapeutics at Buy on expected DCCR approval - Investing.com
HC Wainwright Begins Coverage on Soleno Therapeutics (NASDAQ:SLNO) - MarketBeat
Analyst starts Soleno Therapeutics at Buy on expected DCCR approval By Investing.com - Investing.com UK
High Growth Tech Stocks To Watch In September 2024 - Simply Wall St
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):